Delivery of the p53 tumor suppressor gene into lung cancer cells by an adenovirus/DNA complex
- PMID: 9171938
Delivery of the p53 tumor suppressor gene into lung cancer cells by an adenovirus/DNA complex
Abstract
An adenovirus/DNA complex was constructed by chemically linking poly-L-lysine to the capsid of the replication-defective adenovirus dl312, allowing for coupling with plasmid DNA by an ionic interaction. We have previously demonstrated that this adenovirus/DNA complex can efficiently transduce malignant cells with a plasmid expressing the beta-galactosidase gene both in vitro and in vivo. In this report, we show that this system can deliver a therapeutic gene that encodes for the tumor suppressor protein p53 to lung cancer cells, both in vitro and in vivo, leading to significant biological effects. Transfection of the p53-negative human lung cancer cell line H1299 with the adenovirus/DNA complex carrying a plasmid expressing the p53 gene resulted in high levels of p53 protein and induction of apoptosis. Injection of the complex carrying the p53 gene to subcutaneous tumor sites 5 days after tumor cell implantation resulted in a significant inhibition of tumorigenicity as measured by the number and size of tumors that developed 21 days after treatment. Three and six injections of the complex carrying the p53 gene into H1299 subcutaneous tumor nodules led to significant dose-related tumor growth suppression 18 days after the first injection compared with control-treated tumors. This adenovirus/DNA complex, therefore, is capable of efficiently delivering the p53 gene into malignant cells in vitro and in vivo and now provides a general gene delivery vector that is simple to construct and capable of testing therapeutic genes in malignant cells.
Similar articles
-
Gene delivery into malignant cells in vivo by a conjugated adenovirus/DNA complex.Cancer Gene Ther. 1997 May-Jun;4(3):183-90. Cancer Gene Ther. 1997. PMID: 9171937
-
Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts.Cancer Gene Ther. 1997 Mar-Apr;4(2):129-38. Cancer Gene Ther. 1997. PMID: 9080122
-
Viral and non-viral vectors for cancer gene therapy.Anticancer Res. 1998 Sep-Oct;18(5A):3241-5. Anticancer Res. 1998. PMID: 9858889
-
Anti-oncogene and tumor suppressor gene therapy--examples from a lung cancer animal model.In Vivo. 1994 Nov-Dec;8(5):755-69. In Vivo. 1994. PMID: 7727723 Review.
-
[A phase I trial of adenoviral p53 gene therapy for non-small cell lung cancer].Nihon Geka Gakkai Zasshi. 1999 Nov;100(11):749-55. Nihon Geka Gakkai Zasshi. 1999. PMID: 10629843 Review. Japanese.
Cited by
-
The molecular basis of lung cancer: molecular abnormalities and therapeutic implications.Respir Res. 2003;4(1):12. doi: 10.1186/1465-9921-4-12. Epub 2003 Oct 7. Respir Res. 2003. PMID: 14641911 Free PMC article. Review.
-
Fhit-Fdxr interaction in the mitochondria: modulation of reactive oxygen species generation and apoptosis in cancer cells.Cell Death Dis. 2019 Feb 15;10(3):147. doi: 10.1038/s41419-019-1414-7. Cell Death Dis. 2019. PMID: 30770797 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous